Once-weekly treatment of anemia in patients with cancer: A comparative review of epoetins

Oncology

Volumn 68, Issue 2-3, 2005, Pages 122-129

  Pujade Lauraine, Eric ^a   Topham, Clare ^b  

^a HÔTEL DIEU   (France)

^b St Luke's Cancer Centre   (United Kingdom)

Author keywords

Anemia; Darbepoetin ; Epoetin ; Epoetin

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE;

ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; INJECTION SITE REACTION; LYMPHOPROLIFERATIVE DISEASE; PAIN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; NEOPLASM;

ANEMIA, HYPOCHROMIC; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; NEOPLASMS;

EID: 23844450044     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086957     Document Type: Review

References (45)

1. Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
2. Cella D: Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998;25(suppl 7):43-46.
3. Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-2221.
4. Albain KS, Crowley JJ, LeBlanc M, Livingston RB: Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
5. Robnett TJ, Machtay M, Hahn SM, Shrager JB, Friedberg JS, Kaiser LR: Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J 2002;8:263-267.
6. Van Belle SJ-P, Cocquyt V: Impact of haemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol/Hematol 2003;47:1-11.
7. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
8. Walker RH: Special report: Transfusion risks. Am J Clin Pathol 1987;88:374-378.
9. Goodnough LT, Brecher ME, Kanter MH, Au-Buchon JP: Transfusion medicine. First of two parts - Blood transfusion. N Engl J Med 1999;340:438-447.
10. Coiffier B: Advocating rhEPO as standard practice in Europe for treatment of cancer-related anaemia. Ann Oncol 2003;14:804.
11. Österborg A: Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: What have we learned? Med Oncol 1998:15(suppl 1):S47-S49.
12. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
13. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
14. Henke M, Laszig R, Rübe C, et al: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
15. Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
16. Kaanders JHAM, van der Kogel AJ: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:78-79.
17. Haddad R, Posner M: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:79.
18. Leyland-Jones B, Mahmud S: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80.
19. Blumberg N, Heal JM: Erythropoietin to treat anaemia in patients with head and neck cancer. Lancet 2004;363:80.
20. Glaser CM, Millesi W, Kornek GV, Lang S, Schüll B, Watzinger F, Selzer E, Lavey RS: Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiation Oncology Biol Phys 2001;50:705-715.
21. Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J: Aranesp 980297 Study Group: Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
22. Antonadou D, Cardamakis E, Puglisi M, Malamos N, Throuvalas N: Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies. Eur J Cancer (abstr530) 2001;37(suppl 6):S144.
23. Bohlius JF, Langensiepen S, Schwarzer G, Bennett CL, Engert A: Does erythropoietin improve overall survival in the treatment of patients with malignant diseases? Results of a comprehensive meta-analysis. Blood 2003;102:abstr 709.
24. Ludwig H, Birgegard G, Barrett-Lee P, Krzakowski M: Prevalence and management of anemia in patients with hematologic malignancies and solid tumors: Results from the European Cancer Anaemia Survey (ECAS). Blood 2002;100:abstr 884.
25. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
26. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH: Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
27. Nguyen TV, Trinh GN: Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: Problems of study design and interpretation. J Clin Oncol 2002;20:878.
28. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001;84(suppl 1):3-10.
29. Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, Abraham PA: Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991;50:702-712.
30. Hedenus M, Adriansson M, San Miguel J, Kramer MHH, Schipperus MR, Juvonen E, Taylor K, Belch A, Altés A, Martinelli G, Watson D, Matcham J, Rossi G, Littlewood TJ: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
31. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt K-U, Hörl WH, Krediet RT, Locatelli F, Macdougall IC, Wikström B: Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001;16(suppl 3):22-28.
32. Deray G: Once-weekly erythropoietic therapy: Is there a difference between the available preparations? Nephrol Dial Transplant 2003;18:2455-2456.
33. Coiffier B: Epoetin once weekly in anaemic patients with cancer. Br J Haematol 2004;125:100-101.
34. Coiffier B, The NOW Study Group: Rapid response with epoetin beta (NeoRecormon) once weekly or three times weekly in anemic patients with lymphoid malignancies. Blood 2003;102(11):abstr 3775.
35. Hedenus M, Hansen S, Taylor K, Arthur C, Emmerich B, Dewey C, Watson D, Rossi G, Osterborg A: Darbepoetin alfa 990114 Study Group. Randomized, dose-finding study of darbepoetin alfa in anemic patients with lymphoproliferative malignancies. Br J Haematol 2002;119:79-86.
36. Glaspy JA, Tchekmedyian NS: Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology 2002;16 (suppl 11):23-29.
37. Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB: Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-276.
38. Kotasek D, Steger G, Faught W, Underhill C, Poulsen E, Colowick AB, Rossi G, Mackey J, for the Aranesp 980291 Study Group: Darbepoetin alfa administered once every 3 weeks alleviates anaemia in patients with solid tumors receiving chemotherapy; Results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-2034.
39. Smith RE Jr, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J, for the Aranesp 990111 Study Group: A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer 2003;88:1851-1858.
40. Grzeszczak W, Sulowicz W, Rutkowski B, Ponticelli C, Scanziani R, Durand P-Y, Bajo A, Vargemezis V: Once weekly and once fort-nightly (every two weeks) subcutaneous epoetin beta is effective in PD patients with chronic renal anaemia. Nephrol Dial Transplant 2002;17(suppl 12):abstr O76.
41. McKenzie SR, Heifetz LJ, Duh MS, Piech CT: Effectiveness of epoetin alfa beyond once-weekly dosing schedules in the oncology community practice setting. Blood 2002;100:abstr 5591.
42. Veys N, Dhondt A, Lameire N: Pain at the injection site of subcutaneously administered erythropoietin: Phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998;49:41-44.
43. Vanrenterghem Y, Bárány P, Mann JFE, Kerr PG, Wilson J, Baker NF, Gray SJ: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167-2175.
44. Locatelli F, Baldamus CA, Villa G, Ganea A, Martín de Francisco AL, on behalf of the Study Group: Once-weekly compared with three-times-weekly subcutaneous epoetin β: Results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002;40:119-125.
45. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B, on behalf of the Swedish Study Group: The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: Results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000;15:2014-2019.